Hemostemix Presents at TERMIS 2025, Freiburg, Germany – Newsfile
Freiburg, Germany–(Newsfile Corp. – May 20, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology.Read More
The Heartbeat of World events
Freiburg, Germany–(Newsfile Corp. – May 20, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology.Read More